Is tremfya effective for people who failed humira?

Is Tremfya effective after Humira failure?

Tremfya (guselkumab) targets interleukin-23, a different pathway than Humira’s TNF-alpha inhibition. In patients who lost response to adalimumab, switching to guselkumab produced PASI 90 responses in roughly 60 percent of cases at week 24 in the NAVIGATE trial, compared with 20 percent who stayed on adalimumab. Similar improvements in joint symptoms were seen in psoriatic arthritis patients previously treated with TNF inhibitors.

How quickly does Tremfya work after Humira stops working?

Most patients who had stopped responding to Humira showed measurable skin clearance by week 8 of Tremfya, with continued gains through week 24. Joint pain and swelling scores began to drop by week 12 in the same population.

What happens if someone fails both Humira and Tremfya?

Limited data exist for sequential failure of TNF and IL-23 inhibitors. Many clinicians next consider IL-17 inhibitors (secukinumab, ixekizumab) or JAK inhibitors. Real-world studies show that roughly one-third of patients who fail two different biologics still reach PASI 75 on a third agent, though outcomes vary by disease severity and comorbidities.

Can biosimilars of Humira change the decision to switch to Tremfya?

Humira biosimilars have lowered the cost of staying on a TNF inhibitor, so some payers now require a trial of an adalimumab biosimilar before approving Tremfya. The choice still depends on individual response history and safety considerations rather than price alone.

When does Tremfya’s patent protection end?

Tremfya’s composition-of-matter patent in the United States expires in 2031, with possible extensions. DrugPatentWatch.com lists later formulation and method-of-use patents that could stretch protection into the mid-2030s, delaying biosimilar entry.